#USA #San Antonio #Kazia Therapeutics #Paxalisib #SABCS 2026

Kazia Therapeutics Announces Presence at SABCS 2026

Kazia Therapeutics Limited (NASDAQ: KZIA), an innovative biotechnology firm specializing in oncology treatments, is poised to unveil significant findings at the upcoming San Antonio Breast Cancer Symposium (SABCS) scheduled for December 8-11, 2026. The company will present two abstracts that delve into the unique tumor and immune reprogramming properties of their leading drug candidate, paxalisib.

Overview of Presentations

The selected posters will explore paxalisib’s differentiated biological activity, particularly its impact on tumor and immune responses compared to other dual PI3K/mTOR inhibitors. The two abstracts are:

1. Paxalisib uniquely induces durable tumour and immune reprogramming across breast cancer subtypes, challenging the paradigm that dual PI3K/mTOR inhibitors are biologically equivalent. This research illustrates the potential of paxalisib to induce persistent changes in tumor and immune cell behavior, setting it apart from traditional treatments.

2. Suppression of Local and Metastatic Recurrence by Adjuvant PI3K/mTOR Inhibition Through Durable Immune Epigenetic Rewiring Following Neoadjuvant Chemo-Immunotherapy in Stage III Triple-Negative Breast Cancer. This study focuses on paxalisib’s potential in minimizing local recurrence and metastasis in a clinical model, indicating its promise as part of a comprehensive treatment regimen for challenging breast cancer cases.

Significance of the Research

The insights being presented at SABCS 2026 mark a critical moment for Kazia Therapeutics as it positions itself at the forefront of cancer treatment innovation. The company asserts that paxalisib's unique ability to reprogram both tumor and immune environments is not a common trait among its peers in the dual PI3K/mTOR inhibitor category. Following neoadjuvant chemo-immunotherapy, paxalisib’s distinct mechanism may offer improved outcomes for patients, specifically those diagnosed with Stage III triple-negative breast cancer, a challenging form of the disease that often presents significant treatment resistance.

Kazia’s Mission and Research Focus

Kazia Therapeutics is dedicated to creating therapies that actively reprogram cancer biology while restoring the body’s natural anti-tumor immune response. Its flagship product, paxalisib, is an investigational oral medication that has gained traction across various cancer types, particularly for central nervous system malignancies and advanced breast cancer. Furthermore, the drug has garnered prestigious designations from the U.S. FDA, including Fast Track and Orphan Drug status, emphasizing its potential in addressing critical medical needs.

In addition to paxalisib, Kazia is developing other pioneering therapies, such as NDL2, aimed at overcoming immunotherapy resistance, and MSETC, intended to restore immune signaling pathways in tumors resistant to current treatments. This multifaceted approach positions Kazia as a key player in the oncology field, devoted to advancing innovative solutions for cancer patients.

Conclusion

Kazia Therapeutics’ participation at the SABCS this December underscores its commitment to transforming cancer treatment paradigms through rigorous research and innovative drug development. As they prepare for this critical presentation, the data shared is expected to propel conversations around treatment strategies, emphasizing the differential effects and potential advantages of paxalisib in the oncology landscape. Interested audiences can stay informed about Kazia by visiting their official website or following them on social media.